metabolic drugs

Lilly ADA

Biotech

ADA: Lilly offers deeper glimpse into triple-G obesity candidate

Eli Lilly is keenly aware that the one-size-fits-all approach to obesity and diabetes treatment pioneered by early GLP-1s will soon be obsolete.

Fraiser Kansteiner Jun 6, 2026 3:28pm

climbing rock climber

OrbiMed-backed Pinnacle adds $89M for oral peptides

Mar 26, 2026 10:29am

Measuring tape on top of cash

Zealand pens $2.5B cardiometabolic collab with Chinese biotech

Dec 11, 2025 5:45am

Goal disorientation and lack of vision

Lilly pens $1.2B pact with Sanegene to target metabolic RNA meds

Nov 10, 2025 4:05am

Metallic arrow symbols which are illuminated by blue and magenta lights merge on blue and magenta b

Barinthus enters reverse merger with metabolic disease biotech

Sep 30, 2025 10:39am

Illustration of the concept of layoff and downsizing of staff

Biomea cuts staff, drops leukemia asset in metabolic shift

May 5, 2025 6:59pm